

# EMİNE SARIYILDIZ

## Personal Information

Office Phone: [+90 312 305 1348](tel:+903123051348)

Fax Phone: [+90 312 310 0194](tel:+903123100194)

Other Email: emine.duran@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/emine.duran>

## International Researcher IDs

ORCID: 0000-0003-0257-1061

Yoksis Researcher ID: 107257

## Research Areas

Health Sciences

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group**  
Caminati M., Fassio A., Alberici F., Baldini C., Bello F., Cameli P., Conticini E., Cottin V., Crimi C., Dagna L., et al.  
Allergy: European Journal of Allergy and Clinical Immunology, vol.79, no.2, pp.516-519, 2024 (SCI-Expanded)
- II. **Power Doppler signal at the enthesis and bone erosions are the most discriminative OMERACT ultrasound lesions for SpA: results from the DEUS (Defining Enthesitis on Ultrasound in Spondyloarthritis) multicentre study**  
Di Matteo A., Smerilli G., Di Donato S., Liu A. R., Becciolini A., Camarda F., Cazenave T., Cipolletta E., Corradini D., De Agustín J., et al.  
Annals of the Rheumatic Diseases, 2024 (SCI-Expanded)
- III. **Factors that predict development of chronic kidney disease in patients with rheumatoid arthritis receiving biologic DMARDs and mortality rates**  
Sandal Uzun G., Taghiyeva A., Çakır İ. Y., Moral K., YARDIMCI G. K., Bölek E. Ç., Farisoğulları B., Duran E., AYAN G., ÖZSOY Z., et al.  
International Journal of Rheumatic Diseases, vol.27, no.1, 2024 (SCI-Expanded)
- IV. **The predictors of paradoxical reactions, especially psoriasis, to biologic therapy—findings from the TReasure database: a 5-year follow-up study**  
YAĞIZ B., Lermi N., COŞKUN B. N., DALKILIÇ H. E., KİRAZ S., Erden A., Ertenli I., Duran E., BİLGİN E., Yılmaz R., et al.  
Rheumatology (United Kingdom), vol.62, no.12, pp.3962-3967, 2023 (SCI-Expanded)
- V. **Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al.**  
Duran E., Yıldırım B. E. S., Karadağ Ö.  
Clinical and experimental rheumatology, vol.41, 2023 (SCI-Expanded)
- VI. **Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry**  
Duran E., Ozturk Z. O., BİLGİN E., BÜYÜKAŞIK Y., DİZDAR Ö., Yardimci G. K., Farisogullari B., ÖZSOY Z., AYAN G., Uzun G. S., et al.  
Rheumatology and Therapy, vol.10, no.4, pp.969-981, 2023 (SCI-Expanded)

- VII. **Interchangeability and adverse events in originator-rituximab and its biosimilars (CT-P10) among rheumatic patients: a real-life experience**  
Bahap-Kara M., Duran E., Bayraktar-Ekincioglu A., KARADAĞ Ö.  
Internal and Emergency Medicine, vol.18, no.3, pp.791-799, 2023 (SCI-Expanded)
- VIII. **Sinonasal and respiratory outcomes of eosinophilic granulomatosis with polyangiitis patients receiving 100 mg mepolizumab in real-life clinical practice: 1-year follow up study**  
Can Bostan Ö., Duran E., Tuncay G., Cihanbeylerden M., Karadag O., Damadoglu E., Karakaya G., Kalyoncu A. F.  
Journal of Asthma, vol.60, no.5, pp.931-937, 2023 (SCI-Expanded)
- IX. **Reliability assessment of the definition of ultrasound enthesitis in SpA: results of a large, multicentre, international, web-based study**  
Di Matteo A., Cipolletta E., Castaniti G. M. D., Smerilli G., Airoldi C., Aydin S. Z., Becciolini A., Bonfiglioli K., Bruns A., Carrara G., et al.  
RHEUMATOLOGY, vol.61, pp.4863-4874, 2022 (SCI-Expanded)
- X. **Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience**  
SARIYILDIZ E., YILDIRIM T., Taghiyeva A., Bilgin E., ARICI M., Saglam E. A., ÖZEN S., ÜNER M., ERDEM Y., KALYONCU U., et al.  
LUPUS, vol.31, pp.1147-1156, 2022 (SCI-Expanded)
- XI. **Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study**  
BİLGİN E., SARIYILDIZ E., ÜNALDI E., KALYONCU U., KİRAZ S., Ertenli I.  
RHEUMATOLOGY, vol.61, no.9, 2022 (SCI-Expanded)
- XII. **Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results**  
AYAN G., Farisogullari B., BİLGİN E., BÖLEK E. Ç., KubraYardimci G., DURAN E., ÖZSOY Z., Uzun G. S., KILIÇ L., AKDOĞAN A., et al.  
CLINICAL RHEUMATOLOGY, vol.41, no.5, pp.1439-1446, 2022 (SCI-Expanded)
- XIII. **The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?**  
DURAN E., CAN BOSTAN Ö., BİLGİN E., KAYA S. B., BÖLEK E. Ç., ÖZER S., DAMADOĞLU E., APRAŞ BİLGEN Ş. Ş., KARAKAYA G., KARADAĞ Ö.  
INTERNAL AND EMERGENCY MEDICINE, vol.17, no.3, pp.743-751, 2022 (SCI-Expanded)
- XIV. **Is the impact of biologic agents in enteropathic spondylitis different from other spondylitis? Real life data from the HUR-BIO Registry.**  
Farisoğulları B., Yardımcı G. K., Sarı A., Bilgin E., Bölek E. Ç., Duran E., Kılıç L., Akdoğan A., Karadağ Ö., Apraş Bilgen Ş., et al.  
Clinical and experimental rheumatology, vol.40, pp.112-119, 2022 (SCI-Expanded)
- XV. **Cryoglobulinemic vasculitis: having giant steps; but there are still unanswered questions**  
KARADAĞ Ö., DURAN E.  
INTERNAL AND EMERGENCY MEDICINE, vol.16, no.1, pp.33-35, 2021 (SCI-Expanded)
- XVI. **Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience**  
BİLGİN E., Ceylan F., DURAN E., Farisogullari B., BÖLEK E. Ç., YARDIMCI G. K., KILIÇ L., AKDOĞAN A., KARADAĞ Ö., APRAŞ BİLGEN Ş. Ş., et al.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.1, pp.297-308, 2021 (SCI-Expanded)
- XVII. **The frequency of Achilles and plantar calcaneal spurs in gout patients**  
DURAN E., BİLGİN E., ERTEMLİ A. İ., KALYONCU U.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.4, pp.1841-1848, 2021 (SCI-Expanded)
- XVIII. **Vital corner of diagnostic challenge: eosinophilic granulomatosis with polyangiitis or COVID-19 pneumonia?**  
Duran E., Kilic L., Durhan G., Inkaya A. Ç., Guven G. S., Karakaya G., Ariyurek O. M., Karadag O.  
Annals of the rheumatic diseases, 2020 (SCI-Expanded)

**XIX. Frailty prevalence and related factors in the older adult-FrailTURK Project.**

Eyigör S., KUTSAL F. Y., Duran E., Huner B., Paker N., Durmus B., Sahin N., Civelek G. M., Gokkaya K., Dogan A., et al.  
Age (Dordrecht, Netherlands), vol.37, no.3, pp.9791, 2015 (SCI-Expanded)

**Articles Published in Other Journals**

**I. Comparison of lupus nephritis and non-lupus nephritides in patients with systemic lupus erythematosus**

DURAN E., BİLGİN E., KALYONCU U., ERTEMENLİ A. İ., YILDIRIM T., ARICI M., ERDEM Y., Taghiyeva A., AYHAN A., Üner M., et al.  
Ulusal Romatoloji Dergisi, vol.15, no.1, pp.18-24, 2023 (Peer-Reviewed Journal)

**Metrics**

Publication: 20

Citation (WoS): 45

Citation (Scopus): 56

H-Index (WoS): 2

H-Index (Scopus): 3